Advances in First-Line and Second-Line Treatment Research for Renal Cell Carcinoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 January 2027 | Viewed by 563
Editors
Interests: kidney cancer; minimally invasive and robotic surgery; clinical and translational uro-oncology
Special Issues, Collections and Topics in MDPI journals
Interests: minimally invasive urologic surgery; translational research; biostatistics
Special Issues, Collections and Topics in MDPI journals
Interests: uro-oncology; minimally invasive surgery; clinical research
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Renal cell carcinoma (RCC) represents a biologically heterogeneous malignancy whose management has undergone a profound transformation over the past decade. The introduction of immune checkpoint inhibitors, anti-angiogenic agents, and their rational combinations has reshaped the first-line and second-line therapeutic landscape, leading to significant improvements in survival outcomes across risk groups. Nevertheless, optimal treatment sequencing, resistance mechanisms, patient selection, and real-world applicability remain areas of active investigation and unmet clinical need.
This Special Issue aims to provide a comprehensive and up-to-date overview of advances in first-line and second-line treatment research for RCC, bridging translational insights and clinical evidence. Particular emphasis will be placed on novel systemic strategies, biomarkers of response and resistance, comparative effectiveness studies, and evolving treatment algorithms in both clear-cell and non–clear-cell RCC. The scope of this Special Issue is to address innovative therapeutic approaches, precision oncology, and outcome-driven research in urological malignancies.
In this Special Issue, original research articles, systematic reviews, meta-analyses, and comprehensive reviews are welcome. Topics of interest include, but are not limited to, immunotherapy-based combinations, targeted therapies, sequencing strategies, predictive biomarkers, treatment resistance, toxicity management, and real-world evidence. We look forward to receiving high-quality contributions that will advance clinical decision-making and future research in RCC.
You may choose our Joint Special Issue in Clinics and Practice.
Dr. Francesco Ditonno
Prof. Dr. Celeste Manfredi
Dr. Antonio Franco
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- renal cell carcinoma
- immune checkpoint inhibitors
- patient selection
- precision medicine
- biomarkers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
